Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTVNASDAQ:ITRMNASDAQ:LIANNASDAQ:PHXM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$1.58-6.0%$2.10$1.55▼$17.31$38.49MN/A171,643 shs420,073 shsITRMIterum Therapeutics$0.99-0.7%$1.03$0.81▼$3.02$39.60M2.781.05 million shs343,326 shsLIANLianBio$0.38+0.1%$0.28$0.27▼$4.99$41.09M0.231.04 million shs223,918 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/A20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics-5.95%-20.20%-21.00%-63.00%+157,999,900.00%ITRMIterum Therapeutics-1.00%-0.09%+8.08%-31.25%-11.61%LIANLianBio0.00%+2.70%0.00%+94.47%+17.28%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTVArtiva Biotherapeutics2.9865 of 5 stars3.50.00.00.03.31.71.3ITRMIterum Therapeutics2.4932 of 5 stars3.55.00.00.02.60.00.0LIANLianBioN/AN/AN/AN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTVArtiva Biotherapeutics 3.00Buy$17.801,026.58% UpsideITRMIterum Therapeutics 3.00Buy$9.00809.09% UpsideLIANLianBio 0.00N/AN/AN/APHXMPHAXIAM Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PHXM, LIAN, ARTV, and ITRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025ARTVArtiva BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$12.005/15/2025ARTVArtiva BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $18.005/8/2025ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$9.004/8/2025ARTVArtiva BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.003/26/2025ARTVArtiva BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/25/2025ARTVArtiva BiotherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$23.00 ➝ $20.003/25/2025ARTVArtiva BiotherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$18.00 ➝ $18.003/25/2025ARTVArtiva BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTVArtiva Biotherapeutics$250K153.96N/AN/A$7.68 per share0.21ITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/ALIANLianBioN/AN/AN/AN/A$2.71 per shareN/APHXMPHAXIAM Therapeutics$32.66M0.32N/AN/A$7.98 per share0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTVArtiva Biotherapeutics-$65.37MN/A0.00N/AN/AN/A-75.95%-39.51%6/23/2025 (Estimated)ITRMIterum Therapeutics-$24.77M-$0.99N/A∞N/AN/AN/A-71.37%8/13/2025 (Estimated)LIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/APHXMPHAXIAM Therapeutics-$240KN/A0.00∞N/AN/AN/AN/AN/ALatest PHXM, LIAN, ARTV, and ITRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ITRMIterum Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A5/8/2025Q1 2025ARTVArtiva Biotherapeutics-$0.68-$0.83-$0.15-$0.83N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTVArtiva BiotherapeuticsN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTVArtiva BiotherapeuticsN/A13.9313.93ITRMIterum TherapeuticsN/A3.723.58LIANLianBioN/A10.0610.06PHXMPHAXIAM Therapeutics0.231.78N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTVArtiva BiotherapeuticsN/AITRMIterum Therapeutics9.21%LIANLianBio74.85%PHXMPHAXIAM Therapeutics0.40%Insider OwnershipCompanyInsider OwnershipARTVArtiva Biotherapeutics21.40%ITRMIterum Therapeutics9.20%LIANLianBio7.59%PHXMPHAXIAM Therapeutics1.94%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTVArtiva Biotherapeutics8124.36 million19.15 millionN/AITRMIterum Therapeutics1040.00 million36.32 millionNot OptionableLIANLianBio110108.06 million99.86 millionNot OptionablePHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataPHXM, LIAN, ARTV, and ITRM HeadlinesRecent News About These CompaniesPHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until DelistingJune 18 at 4:18 AM | finance.yahoo.comPHAXIAM Therapeutics Announces Judicial Liquidation and DelistingJune 13, 2025 | finance.yahoo.comPHAXIAM Therapeutics: New Postponement of the Offer Review HearingJune 5, 2025 | finance.yahoo.comPHAXIAM Therapeutics: Postponement of the Offer Review HearingMay 23, 2025 | finance.yahoo.comPHAXIAM Therapeutics: Extension of the Observation Period of the Receivership ProcedureMay 5, 2025 | finance.yahoo.comPHAXIAM Therapeutics: Update on the Receivership ProcedureApril 25, 2025 | finance.yahoo.comPhaxiam Therapeutics S.A.March 28, 2025 | wsj.comPHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership ProcedureMarch 15, 2025 | finance.yahoo.comPHAXIAM Therapeutics Announces the Opening of a Receivership Procedure and the Postponement of its 2024 Financial Results PublicationMarch 6, 2025 | finance.yahoo.comPHAXIAM Therapeutics: Press Release Regarding Suspension of TradingMarch 6, 2025 | finance.yahoo.comPHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage TherapyJanuary 31, 2025 | businesswire.comPHAXIAM Therapeutics Announces Its Financial Calendar for 2025January 13, 2025 | finance.yahoo.comPHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under the Compassionate Status in EuropeJanuary 7, 2025 | finance.yahoo.comPHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical StudyDecember 31, 2024 | finance.yahoo.comPHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy areaNovember 27, 2024 | globenewswire.comPHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"November 18, 2024 | globenewswire.comPhaxiam Therapeutics S.A.: PHAXIAM Reports Third-Quarter 2024 Financial InformationNovember 13, 2024 | finanznachrichten.dePHAXIAM Reports Third-Quarter 2024 Financial InformationNovember 13, 2024 | globenewswire.comPHAXIAM Therapeutics S.A. (PHXM.PA)November 6, 2024 | finance.yahoo.comPHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.November 4, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in Value3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedBy Jeffrey Neal Johnson | June 18, 2025View 3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedRH Stock Rockets on Surprise Profit and Tariff ShiftBy Chris Markoch | June 15, 2025View RH Stock Rockets on Surprise Profit and Tariff ShiftPHXM, LIAN, ARTV, and ITRM Company DescriptionsArtiva Biotherapeutics NASDAQ:ARTV$1.58 -0.10 (-5.95%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.63 +0.05 (+3.16%) As of 06/20/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Iterum Therapeutics NASDAQ:ITRM$0.99 -0.01 (-0.70%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.00 +0.01 (+1.01%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.LianBio NASDAQ:LIAN$0.38 +0.00 (+0.05%) As of 06/20/2025LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.PHAXIAM Therapeutics NASDAQ:PHXM$3.10 0.00 (0.00%) As of 06/20/2025PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
